Saama Technologies has partnered with Oracle to offer life sciences industry artificial intelligence (AI) enabled applications to accelerate clinical trials.
Under the partnership, Saama will integrate its smart applications with the Oracle Health Sciences Clinical One platform.
With the ability to accelerate validation of clinical trial data, Saama’s purpose-built clinical applications are technology-agnostic and enable biopharma to take the power of AI further with an ‘Intelligent Clinical Cloud’ architecture.
Saama stated that the new partnership allows pharmaceutical companies with AI-driven real-time insights to expedite their clinical trials, which is now a critical requirement due to the global pandemic.
Oracle Health Sciences Life Science Product Strategy global vice-president James Streeter said: “The current global pandemic reinforced the need for speed and accuracy in clinical development to deliver safe and effective new therapies to patients, not just for Covid-19, but across the spectrum of human disease.
“By connecting Saama’s smart applications to Clinical One Data Collection and DMW, we are able to help our life sciences customers advance their drug development timelines. Saama’s smart applications, combined with the Oracle platform, equip clinical trial teams with real-time insight to make faster decisions.”
The applications including Smart Data Query, Smart Auto Mapper, Smart Programming Analytics & Computing Environment will be available as integrated add-ons to the Oracle Clinical One platform that include Clinical One Data Collection and Data Management Workbench (DMW).
Saama stated that its AI models are trained using several clinical data points and can be easily embedded into the existing infrastructure and business workflows.
This collaboration offers scale, agility, integrated user experience, and quick outcomes from clinical applications.